Objectives/Hypothesis: Sentinel lymph node biopsy (SLNB) is considered one of the most important melanoma advancements to date. Since its inception in 1992, a plethora of data and associated controversies has emerged leading to the question: Is SLNB considered the standard of care for head and neck (HN) cutaneous melanoma?
INTRODUCTION
The incidence of cutaneous melanoma continues to rise at epidemic proportions in the United States, 1,2 with 137,990 new cases of melanoma estimated in 2014. This rate has steadily increased by 2.8% per year since 1981. The lifetime risk of developing melanoma will reach 1 in 50 Americans in 2015. 3 One in four new cases present before the age of 40; given this relatively young age, melanoma is second only to adult leukemia in lost potential life years. Melanoma mortality has also risen by 3% each year since 2004. As many as 9,710 Americans will die from melanoma this year, approximately one patient per hour. 2 In 2010, the total direct cost of treating melanoma in the United States exceeded $2.3 billion. 4 Regional metastasis remains the most important prognostic factor for melanoma recurrence and survival. 5 Up to 20% of patients presenting with a clinically and radiographically N0 neck are harboring occult stage III disease. In an effort to accurately stage patients and identify individuals who may benefit from adjuvant therapy, Donald Morton introduced sentinel lymph node biopsy (SLNB) in 1992. 6 This minimally invasive technique is regarded as one of the most important melanoma advancements to date. 7 Over the past two decades, a plethora of data and associated controversies have emerged. This contemporary review investigates the question: Is SLNB now the standard of care for head and neck (HN) cutaneous melanoma?
RATIONALE BEHIND SLNB
Historically, patients with intermediate thickness melanoma (1.0-3.9 mm) stage I and II disease underwent elective neck dissection (END). Although initial retrospective studies demonstrated a survival benefit, 8 all four prospective, randomized trials failed to replicate the overall survival benefit of END in the absence of regional metastasis. [9] [10] [11] [12] Statistical power remains one challenge in determining the survival benefits of early detection of nodal disease. 13 Only 20% of melanoma patients presenting with localized stage I and II disease actually harbor occult nodal metastasis and would benefit from early removal; END is not expected to impart a survival benefit on the remaining 80% of stage I/II patients with localized disease only. Detecting this small difference requires extremely large clinical trials, with enrollment numbering in the thousands. McMasters et al. point out that the Intergroup Melanoma Surgical Trial (IMST), World Health Organization (WHO), and Mayo Clinic trials lacked adequate statistical power to detect this small survival benefit. 14 An additional challenge in identifying occult nodal metastasis is the minute tumor burden harbored within the node. In an END, entire at-risk nodal basins are given to the pathologist for lymph node identification, which is preformed manually via palpation. The nodes are bivalved and stained with hematoxylin and eosin (H&E). This technique can easily miss occult disease, which can measure as small as 0.1 mm. 3, 15 In addition, only 21% to 23% of positive sentinel lymph node (1SLN) patients are diagnosed using traditional H&E staining. 16, 17 Current National Comprehensive Cancer Network (NCCN) guidelines require only melanoma-specific immunohistochemical staining (IHCS) alone within individual cells to diagnose metastatic disease. 18 Rigorous pathology evaluation of all lymph nodes harvested in an END specimen (to include serial microsectioning and IHCS) is not feasible from a time or cost perspective.
SLNB TECHNIQUE
Because multiple prospective, randomized trials failed to demonstrate an overall survival benefit for patients undergoing END, 8, 10, 11, 19 the NCCN no longer advocates routine END for melanoma. 18 The procedure has been replaced by SLNB, which represents a minimally invasive, cost-effective, and efficient means of staging and screening patients for regional metastasis. 20 SLNB indications are summarized in Table I. In brief, patients undergo preoperative injection of a radioactive colloid. Lymphoscintigraphy is performed to determine the number, location, and laterality of at-risk draining nodal basins (Fig. 1) . Fused single-photon emission computed tomography/computed tomography (SPECT/CT) is emerging as a superior imaging modality because of the increased anatomical three-dimensional detail and improved resolution (Fig. 2) . The largest prospective study comparing SPECT/CT to planar lymphoscintigraphy included 403 melanoma patients. 21 SPECT/ CT was found to be superior, altering the surgical plan in 22% of cases. It yielded a higher number of 1SLNs per patient (2.4 vs. 1.87; P <.001) as well as a higher metastatic rate (0.34 vs. 0.21; P 5.04). At a mean follow-up of 28.8 months, patients undergoing SLNB utilizing SPECT/ CT had a higher disease-free survival (DFS) compared to the lymphoscintigraphy group (94% vs. 79%; P 5.02). Multivariate analysis identified use of SPECT/CT as a factor associated with DFS (hazard ratio [HR] 5 4.11; P 5.02).
Once under anesthesia, patients undergo intraoperative lymphatic mapping with vital blue dye. 6 Approximately 1 mL of dye is injected intradermally into the four quadrants surrounding the primary melanoma lesion. Studies consistently demonstrate increased SLNB sensitivity when visual cues from blue dye are combined with auditory cues from a radionucleotide. 22, 23 Unlike trunk and extremity melanomas, wide local excision (WLE) of the HN primary is performed first, because the close proximity of the tumor and draining lymphatics creates radioactive "shine-through," which renders the gamma probe useless. Following WLE, at risk nodal basins are evaluated for increased radioactivity using a handheld gamma probe (Fig. 3) . By definition, a lymph node demonstrating 10% or greater counters per minute compared to the hottest node ex vivo is considered "sentinel."
24 A 1-to 3-cm incision is made overlying the areas of increased radioactivity. A preauricular incision and facial nerve monitoring are recommended in the parotid region (Fig. 3) . Using a combination of the gamma probe and visual cues from the blue dye, individual SLNs are identified and sent separately for permanent histologic evaluation, because a melanoma frozen sections carries a false negative rate of between 5% and 10%. 25 The evaluation includes serial microsectioning and H&E staining. Melanoma specific IHCS for S-100, melan-A (MART-1), and HMB-45 are performed for all SLNs negative on H&E staining. The mean number of SLNs per patient is 2.4, 17 which allows for a more practical, thorough, and complete histologic evaluation compared to an entire lymphadenectomy specimen. 26 Patients with a 1SLN return to the operating room within 2 weeks of diagnosis for definitive therapeutic lymph node dissection (TLND); patients with a negative biopsy are followed clinically.
The success of SLNB hinges upon communication and a collaborative effort. An experienced nuclear medicine team is imperative because inappropriate administration of the radioactive tracer causes shine through. As noted above, the pathologist plays an extremely critical role given the tedious task of identifying micrometastatic disease. The referring dermatology team is vital in working up and identifying appropriate SLNB candidates. Last, the surgeon requires experience in the SLNB technique. Morton et al. prospectively identified a 55-case learning curve to achieve at least 95% accuracy with SLNB. 25 
SUPPORTING EVIDENCE FOR SLNB
SLNB is considered standard of care in 2014 for eight reasons. First, the pathologic status of the SLN is the most important prognostic factor for melanoma recurrence and survival. In 1999, Gershenwald et al. conducted a multivariate analysis on 580 stage I/II melanoma patients (8.1% HN subsite) and found the SLN status (positive or negative for micrometastasis) to be the most significant prognostic factor for both DFS (HR 5 3.41; P <.00001) and melanoma specific survival (MSS) (HR 5 6.53; P <.0001).
27 Table II lists other recognized prognostic variables for comparison. The largest singleinstitution SLNB study dedicated to HN melanoma prospectively followed 353 patients and reported similar results. 17 Best multivariate model analyses revealed 1SLN status as the strongest factor associated with decreased DFS and MSS (Table III) . At 10 years followup, the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1) trial confirmed sentinel node status as the strongest predictor for disease recurrence and death. 28 Second, lymph node tumor burden (microscopic vs. macroscopic disease) is the second most important prognostic factor following number of nodal metastasis for stage III melanoma. A prospective analysis of 1,429 melanoma patients (trunk, extremity, and HN subsites) with lymph node metastasis identified an improved 5-year survival rate for patients presenting with clinically negative but pathologically positive nodal disease, compared to patients with both clinically and pathologically palpable nodal disease (P <.0001). 29 These data were so compelling that the American Joint Committee on Cancer (AJCC) incorporated SLN status into the revised 2002 sixth edition cancer staging system. 30 This utilization of SLNB for staging was validated in the follow-up multi-institutional prospective trial of 3,307 stage III melanoma patients. 5 Cox multivariate analysis identified the number of metastatic lymph nodes, tumor burden (microscopic vs. macroscopic) at the time of staging, tumor ulceration, and depth of invasion as the most important independent predictors of survival (all P values < .001).
Third, SLNB remains the most specific and sensitive means for regional staging. It is important to recognize that, even in 2014, the SLN technique remains a staging tool no different than magnetic resonance imaging, computed tomography, and positron emission tomography. Cross-sectional imaging using traditional radiographic modalities only identifies 0.5% to 3.7% of occult stage III melanoma cases. [31] [32] [33] [34] Given the minute tumor volume in a 1SLN, it is unsurprising that serial sectioning with melanoma IHCS carries greater sensitivity.
Fourth, SLNB is now incorporated into the current NCCN guidelines. 18 Given the above-noted prognostic significance of a 1SLN, as well as the inability to reliably identify occult nodal disease with radiographic imaging alone, the NCCN panel has incorporated SLNB into the treatment algorithm. Patients meeting criteria listed in Table I warrant a discussion on the utility of SLNB.
Fifth, staging with SLNB imparts a survival benefit. The MSLT-1 trial 28 commenced in 1994 to determine if immediate completion lymphadenectomy yields a survival benefit compared to observation. This study included trunk, extremity, and HN cutaneous melanoma patients. A total of 2,001 stage I/II melanoma patients were randomized to WLE with observation and delayed lymphadenectomy for nodal recurrence versus WLE 1 SLNB with immediate lymphadenectomy for micrometastatic disease (Fig. 4) . A 10-year follow-up demonstrated that SLNB correctly determined the pathologic nodal stage in 96% of cases. Patients with intermediate (1.20-3.5 mm) and thick (>3.5 mm) melanomas in the WLE 1 SLN group demonstrated an improved 10-year DFS compared to their observation counterparts. Although a significant treatment-related difference in MSS was not identified among the entire cohort, this finding was expected given that only 20% of study patients harbored regional disease and would benefit from intervention. Subgroup analysis of patients with nodal disease confirmed an improved MSS in the 35 SLNB is recommended for all patients meeting the criteria listed in Table I , regardless of the primary lesion. Their recommendation followed an evidence-based systematic review of the literature yielding 73 studies.
Seventh, The WHO issued a statement that SLNB is the standard of care for melanoma. 36 This position statement was issued in 1999, and SLNB was recognized as "the starting point for future policies on surgery and adjuvant treatment strategies." Eighth, SLNB allows for accurate staging and identification of a homogeneous population of patients to enroll in clinical trials.
14 Stage III melanoma is a heterogeneous category with broad 5-year survival rates, ranging from 78% for patients with one positive micrometastatic node (stage IIIA) to a dismal 40% for patients with three or more positive nodes (stage IIIC). 5 SLNB remains the most accurate means of regional staging, which is imperative to identify a homogeneous population of patients with like outcomes. Without accurate pathologic staging, stratification is impossible, and the result of clinical trials would be difficult to interpret.
SLNB "CONTROVERSIES"

Feasibility in the HN Region
A 34% discordance between clinical prediction of HN lymphatic drainage and lymphoscintigraphy findings in 97 melanoma cases raised concern about the reliability of SLNB in the watershed lymphatics of the HN region. 37 Concerns for damage to surrounding vital structures, such as the great vessels, facial nerve, and spinal accessory nerve, also limited popularity. 38 Throughout the past two decades, studies have consistently demonstrated that SLNB can be accurately performed in cervical nodal basins without significant risk to the cranial nerves and great vessels. [39] [40] [41] [42] The largest HN SLNB prospective study identified in 352 of 353 cases (99.7%) no reported permanent facial nerve, cranial nerve, or vascular damage. Sixty-nine of 353 patients (19.6%) had a 1SLN biopsy. 17 This 19.6% positivity rate mirrors the results achieved in other anatomic sites such as the trunk and extremities. 10, 43 At a mean follow-up of 48 months, 12 of 283 negative SLN patients where locally free of disease but developed regional recurrence within a previously mapped nodal basin, yielding a false-negative rate of 14.8% (12 false negatives/12 false negatives 1 69 true positives). The negative predictive value of 95.8% and false rate of omission of 4.2% mirrors that of trunk and extremity melanoma, thus demonstrating feasibility of SLNB in the HN region.
SLNB Safety in the Parotid Basin
Overall, 25% to 30% of HN cutaneous melanomas drain to the parotid nodal basin, 37, 39 where injury to the facial nerve has led some surgeons to advocate for superficial parotidectomy over SLNB. 38 Numerous studies have demonstrated that SLNB can be reliably and safely performed within the parotid nodal basin, especially when utilizing continuous facial nerve monitoring. 39, 44, 45 Inflammation and fibrosis from SLNB was thought to place the facial nerve at increased risk when a therapeutic superficial parotidectomy was required after a 1SLNB. 38 Erman et al. reported preservation of facial nerve function in all patients undergoing therapeutic superficial parotidectomy following a positive SLNB. 17 
In-transit Metastasis
Authors have suggested that SLNB increases the risk of in-transit metastasis (ITM), which is defined as intralymphatic tumor dissemination within cutaneous or subcutaneous tissue located between the primary lesion and draining nodal basin. [46] [47] [48] ITM presents a therapeutic challenge and carries a poor prognosis. 30 Original reports citing increased ITM following SLNB often entailed pooled data from small cohorts, and failed to control for important prognostic factors such as tumor thickness and ulceration. 46, 49 A follow-up prospective review comparing 4,412 patients undergoing WLE, WLE with SLNB, and elective lymph node dissection (ELND) identified a correlation between ITM and increasing Breslow depth, Clark level, and T stage. 50 A statistically significant difference between ITM and tumor recurrence was not found among the treatment groups, once adjustment was made for T-stage, age, sex, tumor thickness, and site. Additional studies have concluded that it is the tumor biology, as opposed to the surgical procedure (SLNB, ELND), that dictates melanoma metastatic behavior. 46, 51 Finally, a correlation between ITM and SLNB was not reported with MSLT-1, thus negating this concern. 25 
FUTURE SLNB ENDEAVORS
Future SLNB research endeavors hold exciting promise. In an effort to investigate the therapeutic potential of SLNB, recent research efforts focus on identifying markers of both the primary lesion and SLN, which are predictive of tumor remaining in nonSLNs. [52] [53] [54] Such markers may allow identification of a subset of 1SLN patients who do not require formal TLND. Unfortunately, current studies have failed to identify a consistent and 100% accurate marker. For this reason, the ongoing MSLT-II trial is designed to investigate the indications for TLND following a 1SLNB. 25 It will determine whether immediate TLND provides a survival benefit over postoperative, diligent, ultrasonographic monitoring of the draining nodal basins. The European Organization for Research and Treatment (EORTC) Melanoma Group MINITUB trial is also designed to determine if patients with minimal 1SLN tumor burden require TLND. Until the results of these trials are available, TLND following 1SLNB remains the standard of care. 7, 18, 35 Molecular staging of melanoma has also gained increased interest. Reverse transcriptase polymerase chain reaction (RT-PCR) analysis of SLNs for melanomaassociated genes such as MART-1, tyrosinase, and tyrosinase-related protein 2 (TRP-2) have proven helpful in identifying a subset of patients harboring occult nodal disease at a submicroscopic level that cannot be detected with traditional IHCS. [55] [56] [57] In one study, 30% (49 of 162) of patients with at least one melanoma marker identified with RT-PCR experienced an increased rate of recurrence despite a negative SLNB. 58 Currently, RT-PCR carries a high false-positive rate attributed to the inability to differentiate melanoma cells from occult benign nevus cells. Through future research efforts, molecular staging may prove helpful in the identification of a subset of high-risk melanoma patients who develop nodal or distant metastases despite presentation with a thin primary tumor. 59 Near-infrared (NIR) fluorescence utilizing indocyanine green (ICG) provides the surgeon real-time transcutaneous visualization of superficial draining lymphatic channels. 60 The fluorescence signal potentially aids the pathologist in preparing and analyzing SLNs. 61, 62 Optical imaging with ICG as a lymphatic tracer has been successfully applied in various cancers. 63 Four dedicated cutaneous carcinoma studies have been published. [64] [65] [66] [67] The investigations are limited to case reports and small series for a total of 42 patients. Although NIR fluorescence has outperformed traditional blue dye in several SLN clinical trials, 62, 68, 69 tissue depth and large body mass index remains the rate-limiting factor. A hybrid tracer combining ICG with 99m Tc-radioactive colloid has been introduced to increase depth of detection and lengthen retention time of the tracer. 69 The application of SLN optical imaging remains investigational at present but is promising.
Application in Thin Melanomas
The majority of SLNB studies focus upon intermediate thickness melanomas, which carry approximately a 20% rate of occult nodal metastasis. The utility of this technique in thin melanomas remains to be determined. Morton et al. could not draw meaningful conclusions from the 340 MSLT-1 patients with thin melanomas measuring <1.20 mm invasion. 28 A meta-analysis of SLN positivity in thin melanomas 1 mm identifies a pooled occult nodal disease rate of 5.6%. 70 Consistent clinical and histopathologic criteria to reliability identify this small at-risk thin melanoma populaiton is lacking. Future studies are required and will need to balance benefit with cost and associated morbidity.
CONCLUSION
Regional metastasis remains the most important prognostic factor in melanoma. Decreased melanoma mortality ultimately hinges upon accurate staging, especially because the majority of stage III melanoma patients are now diagnosed with micrometastatic as opposed to macrometastatic disease. 71 SLNB represents a minimally invasive, cost-effective, and efficient means of staging and screening patients for regional metastasis. 20 It is now considered the standard of care for intermediate thickness melanomas as supported by its incorporation into the AJCC staging system, 5 NCCN guidelines, 18 and numerous oncology consensus statements. 35, [72] [73] [74] BIBLIOGRAPHY
